We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Subscribe To Our Newsletter & Stay Updated
